The Society for Immunotherapy of Cancer (SITC) Cancer Immunotherapy Guidelines are a collection of consensus statements developed by experts to help oncologists determine when and how to best use immunotherapy to treat their patients. The guidelines are developed using a systematic process to ensure the recommendations are unbiased, relevant, and facilitate clinical decision-making. The guidelines will be evaluated and updated on an ongoing basis.
Prior to publication of each guideline, an open comment period is launched to allow the general public opportunity to review a draft copy of the guideline and provide feedback, with the goal of further improving the draft. Click here to learn more about the SITC Cancer Immunotherapy Guidelines open comment period.
In response to the ever-growing demand for expert guidance on the optimal use of immunotherapy treatments, our Cancer Immunotherapy Guidelines committees have developed consensus statements for cutaneous melanoma, genitourinary malignancies (renal, prostate and bladder carcinoma), hematologic malignancies (multiple myeloma, lymphoma and acute leukemia) and non-small cell lung cancer.
Work on new guidelines for head and neck cancers is currently underway. These disease-specific Cancer Immunotherapy Guidelines offer a vital resource for the practicing oncology community.
Published May 30, 2018 in Journal for ImmunoTherapy of Cancer (JITC) as "An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0."
Published Nov. 15, 2016 in the Journal for ImmunoTherapy of Cancer (JITC) as "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma."
Published Dec. 20, 2016 in the Journal for ImmunoTherapy of Cancer (JITC) as "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma."
Published Aug. 15, 2017 in the Journal for ImmunoTherapy of Cancer (JITC) as "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma."
Published Dec. 20, 2016 in the Journal for ImmunoTherapy of Cancer (JITC) as "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia."
Published July 17, 2018 in Journal for ImmunoTherapy of Cancer (JITC) as "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)"
Key points from SITC's Cancer Immunotherapy Guidelines have been distilled into Pocket Guides. These condensed, easily accessible versions of the full Cancer Immunotherapy Guidelines are a quick-reference tool available in both digital and print.
Download SITC's Cancer Immunotherapy Pocket Guides on any desktop or mobile device free today.*
*Available only through the Guideline Central App.
ORDER Digital/Print Guides
SITC follows the 2011 Institute of Medicine’s “Standards for Developing Trustworthy Clinical Practice Guidelines” to assure a fair, transparent and balanced process for creating each consensus statement; therefore, each Cancer Immunotherapy Guidelines subcommittee comprises a comprehensive mix of academic physicians and researchers, nurses, patients, and patient advocates invited from institutions across the United States.
Each expert committee addresses knowledge gaps in our understanding of immunotherapy treatments for their disease specialty, and develops evidence-based recommendations by evaluating the published literature and providing their opinions on key issues, documenting alternative opinions when they occur.
Cancer rates across the Middle East are expected to double between 2012 and 2030, according to World Health Organization (WHO) estimates-the highest relative increase of any region globally. This rise is caused by a combination of environmental ...
The cited editorial states that even with modest survival benefits, tripling of PFS as related to the PACIFIC trial of use of durvalumab immediately after chemoradiotherapy is commendable. Given minimal side effects, its addition should be considered ...
Dear Colleagues ,
Sidra Medicine is proud to host Qatar's first International Workshop on Engineered Immune Cells in Cancer Immunotherapy (EICCI): from Discovery to "Off-the shelf" Development.
Translating the potency of the anti-cancer immune ...
Dear Colleagues ,
It is our distinct pleasure to invite you to attend the Global Conference on Cancer & Oncology Research taking place at Dubai, UAE.
Date: Monday 04 and Tuesday 05 March 2019
Venue: Radisson Blu Hotel, Dubai Waterfront ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com